Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Neuse CJ"'
Autor:
Bustoros M; Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.; Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Anand S; Broad Institute of MIT & Harvard, Cambridge, MA, USA.; Boston University School of Medicine, Boston, MA, USA., Sklavenitis-Pistofidis R; Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.; Broad Institute of MIT & Harvard, Cambridge, MA, USA., Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Boyle EM; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Zhitomirsky B; Broad Institute of MIT & Harvard, Cambridge, MA, USA., Dunford AJ; Broad Institute of MIT & Harvard, Cambridge, MA, USA., Tai YT; Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA., Chavda SJ; Division of Hematology, University College London, London, UK., Boehner C; Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA., Neuse CJ; Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.; University of Münster Medical School, Münster, Germany., Rahmat M; Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA., Dutta A; Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA., Casneuf T; Janssen Research and Development, Beerse, Belgium., Verona R; Janssen Research and Development, Spring House, PA, USA., Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Trippa L; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Stewart C; Broad Institute of MIT & Harvard, Cambridge, MA, USA., Walker BA; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, USA., Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Bergsagel PL; Division of Hematology, Mayo Clinic, Scottsdale, AZ, USA., Yong K; Division of Hematology, University College London, London, UK., Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Aguet F; Broad Institute of MIT & Harvard, Cambridge, MA, USA., Getz G; Broad Institute of MIT & Harvard, Cambridge, MA, USA. gadgetz@broadinstitute.org.; Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA, USA. gadgetz@broadinstitute.org., Ghobrial IM; Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu.; Broad Institute of MIT & Harvard, Cambridge, MA, USA. Irene_Ghobrial@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2022 Jun 15; Vol. 13 (1), pp. 3449. Date of Electronic Publication: 2022 Jun 15.
Autor:
Neuse CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Medicine A, Hematology and Oncology, Münster University Hospital, Münster, Germany., Lomas OC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Schliemann C; Department of Medicine A, Hematology and Oncology, Münster University Hospital, Münster, Germany., Shen YJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Manier S; Service des Maladies du Sang, CHU Lille, Lille, France., Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Mark_bustoros@dfci.harvard.edu.; Center for Prevention of Progression, Dana-Farber Cancer Institute, Boston, MA, USA. Mark_bustoros@dfci.harvard.edu., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Center for Prevention of Progression, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2887-2897. Date of Electronic Publication: 2020 Jul 10.
Autor:
Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA., Zhitomirsky B; Broad Institute of MIT and Harvard, Cambridge, MA., Dunford AJ; Broad Institute of MIT and Harvard, Cambridge, MA., Salem K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Tai YT; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Anand S; Broad Institute of MIT and Harvard, Cambridge, MA., Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Chavda SJ; Department of Hematology, University College London, London, United Kingdom., Boehner C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Elagina L; Broad Institute of MIT and Harvard, Cambridge, MA., Neuse CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Faculty of Medicine, University of Münster, Münster, Germany., Cha J; Broad Institute of MIT and Harvard, Cambridge, MA., Rahmat M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Taylor-Weiner A; Broad Institute of MIT and Harvard, Cambridge, MA., Van Allen E; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Kumar S; Division of Hematology, Mayo Clinic, Rochester, MN., Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Leshchiner I; Broad Institute of MIT and Harvard, Cambridge, MA., Morgan EA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Laubach J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Casneuf T; Janssen Research and Development, Beerse, Belgium., Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Trippa L; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.; Harvard T.H. Chan School of Public Health, Boston, MA., Aguet F; Broad Institute of MIT and Harvard, Cambridge, MA., Stewart C; Broad Institute of MIT and Harvard, Cambridge, MA., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Yong K; Department of Hematology, University College London, London, United Kingdom., Bergsagel PL; Division of Hematology, Mayo Clinic, Scottsdale, AZ., Manier S; Department of Hematology, CHU Lille, University of Lille, Lille, France., Getz G; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Jul 20; Vol. 38 (21), pp. 2380-2389. Date of Electronic Publication: 2020 May 22.
Autor:
Bustoros M; 1 Dana-Farber Cancer Institute, Boston, MA.; 3 Harvard Medical School, Boston, MA., Sklavenitis-Pistofidis R; 1 Dana-Farber Cancer Institute, Boston, MA.; 3 Harvard Medical School, Boston, MA., Kapoor P; 4 Mayo Clinic, Rochester, MN., Liu CJ; 1 Dana-Farber Cancer Institute, Boston, MA.; 5 Tapei Veterans General Hospital, Taipei, Taiwan.; 6 National Yang-Ming University, Taipei, Taiwan., Kastritis E; 7 National and Kapodistrian University of Athens, Athens, Greece., Zanwar S; 4 Mayo Clinic, Rochester, MN., Fell G; 1 Dana-Farber Cancer Institute, Boston, MA., Abeykoon JP; 4 Mayo Clinic, Rochester, MN., Hornburg K; 1 Dana-Farber Cancer Institute, Boston, MA., Neuse CJ; 1 Dana-Farber Cancer Institute, Boston, MA.; 8 University of Münster Faculty of Medicine, Münster, Germany., Marinac CR; 1 Dana-Farber Cancer Institute, Boston, MA.; 2 Harvard T.H. Chan School of Public Health, Boston, MA., Liu D; 1 Dana-Farber Cancer Institute, Boston, MA.; 3 Harvard Medical School, Boston, MA., Soiffer J; 1 Dana-Farber Cancer Institute, Boston, MA.; 9 University of Miami Miller School of Medicine, Miami, FL., Gavriatopoulou M; 7 National and Kapodistrian University of Athens, Athens, Greece., Boehner C; 1 Dana-Farber Cancer Institute, Boston, MA.; 10 University of Massachusetts, Boston, MA., Cappuccio JM; 1 Dana-Farber Cancer Institute, Boston, MA., Dumke H; 1 Dana-Farber Cancer Institute, Boston, MA., Reyes K; 1 Dana-Farber Cancer Institute, Boston, MA., Soiffer RJ; 1 Dana-Farber Cancer Institute, Boston, MA.; 3 Harvard Medical School, Boston, MA., Kyle RA; 4 Mayo Clinic, Rochester, MN., Treon SP; 1 Dana-Farber Cancer Institute, Boston, MA.; 3 Harvard Medical School, Boston, MA., Castillo JJ; 1 Dana-Farber Cancer Institute, Boston, MA.; 3 Harvard Medical School, Boston, MA., Dimopoulos MA; 6 National Yang-Ming University, Taipei, Taiwan., Ansell SM; 4 Mayo Clinic, Rochester, MN., Trippa L; 1 Dana-Farber Cancer Institute, Boston, MA.; 2 Harvard T.H. Chan School of Public Health, Boston, MA., Ghobrial IM; 1 Dana-Farber Cancer Institute, Boston, MA.; 3 Harvard Medical School, Boston, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Jun 01; Vol. 37 (16), pp. 1403-1411. Date of Electronic Publication: 2019 Apr 16.
Autor:
Bustoros M; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Liu CJ; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Hornburg K; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Kanellias N; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Kim G; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Liu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Gavriatopoulou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Marinac CR; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Roussou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Migkou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Noonan K; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Reyes K; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Rivotto B; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Neuse CJ; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Ziogas DC; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Laubach J; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Richardson PG; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Ghobrial IM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Publikováno v:
American journal of hematology [Am J Hematol] 2019 May; Vol. 94 (5), pp. E146-E149. Date of Electronic Publication: 2019 Mar 06.